Show simple item record

AuthorNazmul, Islam
AuthorXu, Chang
AuthorLau, Colleen L.
AuthorMills, Deborah J.
AuthorClark, Justin
AuthorDevine, Gregor J.
AuthorHugo, Leon E.
AuthorGyawali, Narayan
AuthorThalib, Lukman
AuthorFuruya-Kanamori, Luis
Available date2022-05-18T05:14:09Z
Publication Date2022-05-12
Publication NameVaccine
Identifierhttp://dx.doi.org/10.1016/j.vaccine.2022.04.079
CitationIslam, Nazmul, Chang Xu, Colleen L. Lau, Deborah J. Mills, Justin Clark, Gregor J. Devine, Leon E. Hugo, Narayan Gyawali, Lukman Thalib, and Luis Furuya-Kanamori. "Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis." Vaccine (2022).
ISSN0264410X
URIhttps://www.sciencedirect.com/science/article/pii/S0264410X22005357
URIhttp://hdl.handle.net/10576/30986
AbstractBackgroundThe burden of Japanese encephalitis (JE) is substantial and is arguably one of the most serious viral encephalitic diseases with high case fatality and no specific treatment. JE vaccines are the only available mean to prevent the disease; however, the long-term persistence of antibodies, boostability, and interchangeability between different vaccine classes are not well understood. MethodsTo summarise the evidence, PubMed, Embase, and Cochrane CENTRAL were systematically searched from their inception to March 2021. Dose-response meta-analysis was utilised to synthesise the proportion of individuals who were seropositive over time after a primary vaccination course and a booster dose. Proportion meta-analysis was conducted to estimate the proportion of individuals who were seropositive as well as those who reported adverse events following a booster dose with a different vaccine class. ResultsOf 1053 publications retrieved, 27 studies with 4,558 participants were included. Of these, 11 studies assessed persistence of antibodies, 14 studies boostability, and 8 vaccine class interchangeability. The pooled seropositivity, 1-year after primary vaccination was 83.4% (95 %CI 78.2–89.5%) and remained stable for up to 5 years (82.7%; 95 %CI 76.1–89.4%). Rapid anamnestic response was observed 10 days post-booster dose, the proportion of individuals who were seropositive reached 96.9% (95 %CI 95.9–97.8%) and remained > 95% for up to 6 years. Inactivated mouse brain-derived vaccines followed by a booster dose of a different vaccine class was effective (i.e. seropositive 99%) and well tolerated. ConclusionsA booster dose after the primary vaccination is effective and further booster doses may be needed after 7 years. Inactivated mouse brain-derived vaccine followed by a booster with a newer vaccine class is effective and safe; although, there is a paucity of data related to newer classes of vaccines interchangeability.
Languageen
PublisherElsevier
SubjectAntibodies, booster
Dose-response
Immunisation
Meta-analysis
Seroprotection
TitlePersistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis
TypeArticle Review
dc.accessType Full Text


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record